anti-Coagulation Factor IX (F9) Antibodies

F9 encodes vitamin K-dependent coagulation factor IX that circulates in the blood as an inactive zymogen. Additionally we are shipping Coagulation Factor IX Kits (75) and Coagulation Factor IX Proteins (38) and many more products for this protein.

list all antibodies Gene Name GeneID UniProt
F9 2158 P00740
F9 14071 P16294
F9 24946 P16296
How to order from antibodies-online
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Order online
  • orders@antibodies-online.com

Top anti-Coagulation Factor IX Antibodies at antibodies-online.com

Showing 10 out of 290 products:

Catalog No. Reactivity Host Conjugate Application Images Quantity Supplier Delivery Price Details
Cow Rabbit Un-conjugated WB Western blot analysis of Factor IX expression in HepG2 (A), NIH3T3 (B) whole cell lysates. 200 μL Log in to see 13 to 14 Days
$487.50
Details
Human Rabbit Un-conjugated WB   200 μL Log in to see 13 to 14 Days
$487.50
Details
Human Rabbit Un-conjugated WB   200 μL Log in to see 13 to 14 Days
$487.50
Details
Human Rabbit Un-conjugated ELISA, WB 100 μg Log in to see 14 to 16 Days
$247.82
Details
Human Rabbit Un-conjugated ELISA, WB 100 μg Log in to see 14 to 16 Days
$312.53
Details
Human Rabbit Un-conjugated ICC, IF, IHC, IHC (p) Immunohistochemistry-Paraffin: Factor IX Antibody [NBP1-33581] - Paraffin-embedded Colon ca, using antibody at 1:250 dilution. Immunohistochemistry-Paraffin: Factor IX Antibody [NBP1-33581] - Paraffin-embedded rat liver diluted 1:500. 100 μL Log in to see 8 to 11 Days
$516.98
Details
Human Rabbit Un-conjugated ELISA, WB   100 μL Log in to see Available
$181.73
Details
Human Rabbit Un-conjugated ELISA, IHC, WB Western blot analysis of extracts of HO-8910, using F9 antibody. The lane on the left is treated with the antigen-specific peptide. ABIN6276737 at 1/100 staining Mouse liver tissue by IHC-P. The sample was formaldehyde fixed and a heat mediated antigen retrieval step in citrate buffer was performed. The sample was then blocked and incubated with the antibody for 1.5 hours at 22¡ãC. An HRP conjugated goat anti-rabbit antibody was used as the secondary 100 μL Log in to see 11 to 12 Days
$390.77
Details
Human Rabbit Un-conjugated IHC, WB Western blot analysis of extracts of various cell lines, using F9 antibody. 100 μL Log in to see 11 to 13 Days
$366.77
Details
Human Mouse Un-conjugated IP, RNAi, ELISA, WB Western blot analysis of F9 over-expressed 293 cell line, cotransfected with F9 Validated Chimera RNAi (Lane 2) or non-transfected control (Lane 1). Blot probed with F9 monoclonal antibody (M01), clone 2C9. GAPDH ( 36.1 kDa ) used as specificity and loading control. Detection limit for recombinant GST tagged F9 is approximately 0.1ng/ml as a capture antibody. 100 μg Log in to see 11 to 12 Days
$364.00
Details

Top referenced anti-Coagulation Factor IX Antibodies

  1. Human Polyclonal Coagulation Factor IX Primary Antibody for IF (p), IHC (p) - ABIN1387087 : Yang, Bae, Jung, Park, Chung, Seok, Roh, Han, Oh, Sohn, Jeong, Cho: Surface functionalization-specific binding of coagulation factors by zinc oxide nanoparticles delays coagulation time and reduces thrombin generation potential in vitro. in PLoS ONE 2017 (PubMed)

More Antibodies against Coagulation Factor IX Interaction Partners

Human Coagulation Factor IX (F9) interaction partners

  1. Major bleeding in a patient with warfarin-hypersensitive and factor IX propeptide variant, p.Ala37Thr, who was treated with a direct oral anti-Xa inhibitor.

  2. The majority of plasma samples from burn patients have active FXIa and FIXa, with a significant fraction of them having active TF. The concentration of all three proteins varies in a wide range.

  3. Protein S is an important in vivo inhibitor of FIXa. Disruption of the interaction between PS and FIXa causes an increased rate of thrombus formation in mice.

  4. F8 and F9 gene variants result from a founder effect in two large French haemophilia cohorts

  5. available to predict the inhibitory activity on FIXa. On the basis of pharmacophore modeling, molecular docking, and 3D-QSAR modeling screening, six molecules are

  6. Report induced pluripotent stem cell model characterizing mutated F9 mRNA in hemophilia B.

  7. genetic association studies in cohort of patients in Switzerland: Data suggest that F9 propeptide mutation-associated hypersensitivity to vitamin K antagonist anticoagulants is rare phenomenon; F9 propeptide mutation Ala37Thr confers high sensitivity to warfarin.

  8. Higher FIX antigen levels are associated with incident coronary heart disease in blacks but not in whites; the association of FXI levels with ischemic stroke is slightly attenuated after adjusting for stroke risk factors.

  9. Report a diagnostic algorithm that can reliably identify pathogenic variants of factor 8/9 and von Willebrand factor and diagnose patients with hemophilia A, hemophilia B or von Willebrand disease.

  10. a computational approach was conducted to select suitable location(s) for introducing new N-glycosylation sites into the human coagulation factor IX.

  11. The pathogenic basis for one synonymous mutation (Val107Val) in the F9 gene associated with haemophilia B was determined.

  12. caspase-3 inhibitors also suppressed the attenuation of cell adhesion and phosphorylation of p38 MAPK by EGF-F9. Our data indicated that EGF-F9 activated signals for apoptosis and induced de-adhesion in a caspase-3 dependent manner.

  13. Specific factor IX mRNA and protein features that favor drug-induced readthrough over recurrent nonsense mutations have been reported.

  14. Here we optimize the transient transfection of HEK293T/17 cells for the production of AAV human factor IX in a disposable fixed-bed bioreactor, the iCELLis((R)) Nano (PALL Corporation).

  15. Our results confirm the rare event of Haemophilia A and haemophilia B in the same patient originating from two distinct genetic defects in F8 and F9 genes.

  16. Thus, splicing and protein alterations contribute to define at the molecular level the disease-causing effect of a number of exonic mutations in coagulation FIX exon 5. In addition, our results have a significant impact in the development of splicing-switching therapies in particular for mutations that affect both splicing and protein function

  17. This study confirms the high heterogeneity of molecular defects leading to hemophilia B in Belgium. Six missense variants and 1 in-frame deletion, previously unreported, were predicted to affect FIX protein function.

  18. this study shows that targeted high-throughput sequencing is an effective technique to detect the F9 gene mutations in hemophilia patients

  19. Patient 1 had a 149-kb deletion with breakpoints 90-kb upstream and 30-kb downstream from F9. Patients 2 and 3 showed 273-kb and 1.19-Mb deletions respectively. Patient 4 had two deleted regions: a 1663-bp deletion 1.34-Mb upstream from F9 and a 7.2-Mb deletion including F9.

  20. Factor IX mutation was found in every family: eight had large deletions, three had small deletions (<10 base pair) and 102 had single base pair substitutions (69 missense, 26 nonsense, four splice site and three promoter).

Mouse (Murine) Coagulation Factor IX (F9) interaction partners

  1. Protein S is an important in vivo inhibitor of FIXa. Disruption of the interaction between PS and FIXa causes an increased rate of thrombus formation in mice.

  2. Authors investigated the interaction of coagulation factor IX in the development of atherosclerosis. Severe deficiency of FIX did not protect the animals from the development of atherosclerotic plaques in the aortic areas.

  3. activation peptide of factor IX regulates endothelial intercellular adhesion and thus could be used in the treatment of vascular hyperpermeability.

  4. structural features within residues of the 39-loop contribute to the resistance of FIXa to inhibition by plasma inhibitors ZPI and TFPI.

  5. Data indicate that the hyperactivating factor IX (FIX)-R338L mutation resulted in a robust 15-fold gain in potency and therefore provides a promising strategy to improve the efficacy, feasibility, and safety of hemophilia gene therapy.

  6. hnRNP A3 is a major liver nuclear protein binding to age related increase element of the factor IX gene.

  7. functional role of binding of F9 to collagen IV in hemostasis.

  8. FIX and FXI deficiency cause similar effects in the carotid artery injury model

  9. findings show coagulation factor IX & complement component C4-binding protein can bind Adenovirus fiber knob domain & provide a bridge for virus uptake through cell surface heparan sulfate proteoglycans & low-density lipoprotein receptor-related protein

  10. Mice lacking plasminogen and fIX (Plg(-/-)/fIX-/-) have lower mortality at age 6 months than Plg(-/-)/fIX+/+ mice

  11. activation of factor IX plays a more important role than that of TF/FVIIa complex activation of factor X in the early hemostatic response to vascular injury.

  12. important role for Lyn in VWF/GPIb-IX-induced integrin activation mediated via the cGMP signaling pathway independently of TXA2 synthesis and also indicate that Lyn is critically important in GPIb-IX-mediated activation of the cGMP pathway

  13. the heparin-binding exosite of factor IXa is a critical regulator of plasma thrombin generation and venous thrombosis

  14. Extravascular factor activity and joint-directed gene transfer may ameliorate hemophilic joint destruction, even in the absence of circulating FIX.

  15. new opportunities to observe genotype-phenotype and structure-function correlations regarding FIX, as well as the interaction of FIX with inflammatory, immune, and tissue repair systems

  16. age-related homeostasis mechanism is essential for spontaneous amelioration of hemophilia B Leyden

Cow (Bovine) Coagulation Factor IX (F9) interaction partners

  1. structural features within residues of the 39-loop contribute to the resistance of FIXa to inhibition by plasma inhibitors ZPI and TFPI.

  2. Mg2+ ions are required to maintain native conformation and in vivo function of factor IX gamma-carboxyglutamic acid domain

Coagulation Factor IX (F9) Antigen Profile

Protein Summary

This gene encodes vitamin K-dependent coagulation factor IX that circulates in the blood as an inactive zymogen. This factor is converted to an active form by factor XIa, which excises the activation peptide and thus generates a heavy chain and a light chain held together by one or more disulfide bonds. The role of this activated factor IX in the blood coagulation cascade is to activate factor X to its active form through interactions with Ca+2 ions, membrane phospholipids, and factor VIII. Alterations of this gene, including point mutations, insertions and deletions, cause factor IX deficiency, which is a recessive X-linked disorder, also called hemophilia B or Christmas disease.

Gene names and symbols associated with F9

  • coagulation factor IXa (f9a) antibody
  • coagulation factor 9 (f9) antibody
  • coagulation factor IX (CpipJ_CPIJ003776) antibody
  • coagulation factor IX (CpipJ_CPIJ009129) antibody
  • coagulation factor IX (CpipJ_CPIJ013063) antibody
  • coagulation factor IX (CpipJ_CPIJ013624) antibody
  • coagulation factor IX (Tsp_01441) antibody
  • coagulation factor 9 S homeolog (f9.S) antibody
  • Coagulation factor IX (fa9) antibody
  • coagulation factor IX (F9) antibody
  • AW111646 antibody
  • Cf-9 antibody
  • Cf9 antibody
  • f9 antibody
  • FIX antibody
  • FIXA antibody
  • HEMB antibody
  • P19 antibody
  • PTC antibody
  • THPH8 antibody
  • zgc:109775 antibody

Protein level used designations for F9

coagulation factor IX , coagulation factor 9 (plasma thromboplastic component, Christmas disease, hemophilia B) , gla domain , coagulation factor 9 , Coagulation factor IX , coagulation factor IX-like , Christmas factor , F9 p22 , FIX F9 , factor 9 , factor IX F9 , plasma thromboplastic component , plasma thromboplastin component , christmas factor , Coagulation factor IX (plasma thromboplastic component, Christmas disease, hemophilia B) , coagulation factor IX (plasma thromboplastic component, Christmas disease, hemophilia B) , factor IX activated protein , factor IX

GENE ID SPECIES
359826 Danio rerio
496659 Xenopus (Silurana) tropicalis
6035113 Culex quinquefasciatus
6041549 Culex quinquefasciatus
6046266 Culex quinquefasciatus
6047200 Culex quinquefasciatus
10911295 Trichinella spiralis
100049721 Xenopus laevis
100380442 Salmo salar
100398468 Callithrix jacchus
2158 Homo sapiens
14071 Mus musculus
24946 Rattus norvegicus
280688 Bos taurus
100009113 Oryctolagus cuniculus
100135464 Cavia porcellus
397518 Sus scrofa
493973 Felis catus
374258 Gallus gallus
404015 Canis lupus familiaris
443316 Ovis aries
465887 Pan troglodytes
Selected quality suppliers for anti-Coagulation Factor IX (F9) Antibodies
Did you look for something else?